# DiaMedica Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights
Canonical URL: https://biopharmsignal.com/news/DMAC/diamedica-therapeutics-reports-first-quarter-2026-financial-results-and-provides-business-highlights
Ticker: DMAC
Company: DiaMedica Therapeutics
Source: DiaMedica Therapeutics
Published: 2026-05-06 20:30 EST
Original Source URL: https://www.diamedica.com
## Article Body
No article body is available yet.
## Recent Company News
- 2026-07-17 20:30 EST — [DiaMedica Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/DMAC/diamedica-announces-inducement-grants-under-nasdaq-listing-rule-5635-c-4-58a5078e) — Source: DiaMedica Therapeutics
- 2026-06-23 12:30 EST — [DiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of DM199 for the Treatment of Fetal Growth Restriction](https://biopharmsignal.com/news/DMAC/diamedica-therapeutics-announces-first-patients-dosed-in-phase-2-trial-of-dm199--97b3dc71) — Source: DiaMedica Therapeutics
- 2026-06-16 12:30 EST — [DiaMedica Receives FDA Feedback on DM199 Preeclampsia Nonclinical Program](https://biopharmsignal.com/news/DMAC/diamedica-receives-fda-feedback-on-dm199-preeclampsia-nonclinical-program-34bd4bf5) — Source: DiaMedica Therapeutics
- 2026-05-27 20:30 EST — [DiaMedica Therapeutics to Present at the Jefferies Global Healthcare Conference 2026](https://biopharmsignal.com/news/DMAC/diamedica-therapeutics-to-present-at-the-jefferies-global-healthcare-conference-2026) — Source: DiaMedica Therapeutics
- 2026-05-20 12:30 EST — [DiaMedica Therapeutics Announces 75% Enrollment Milestone in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial](https://biopharmsignal.com/news/DMAC/diamedica-therapeutics-announces-75-enrollment-milestone-in-remedy2-phase-2-3-acute-ischemic-stroke-trial) — Source: DiaMedica Therapeutics
## Related News
- 2026-07-22 20:05 EST — VKTX — [Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026](https://biopharmsignal.com/news/VKTX/viking-therapeutics-to-report-financial-results-for-second-quarter-2026-on-july--bbf2553f)
- 2026-07-22 20:01 EST — AXON — [Axon to Release Second Quarter 2026 Earnings on August 5, 2026](https://biopharmsignal.com/news/AXON/axon-to-release-second-quarter-2026-earnings-on-august-5-2026-66120902)
- 2026-07-22 12:39 EST — ARTL — [New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy — Reinforcing the Case for Artelo's Optimized ART12.11 CBD Composition](https://biopharmsignal.com/news/ARTL/new-analysis-of-over-50-studies-showed-that-all-the-non-prescription-cbd-product-a3445432)
- 2026-07-22 12:30 EST — NRSN — [NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS](https://biopharmsignal.com/news/NRSN/neurosense-advances-primec-toward-new-drug-submission-to-health-canada-for-als-721c198c)
- 2026-07-22 12:30 EST — PRGO — [Perrigo to Release Second Quarter 2026 Financial Results on August 5, 2026](https://biopharmsignal.com/news/PRGO/perrigo-to-release-second-quarter-2026-financial-results-on-august-5-2026-ff2ea2a5)